FDA Releases Broad Animal Dewormer Testing Guidance
Published Date: 6/24/2026
Notice
Summary
The FDA just released new guidance to help companies test worm-killing medicines for animals in a way that’s accepted worldwide. This makes it easier and faster for vets and drug makers to prove their products work, saving time and money. If you’re in the animal medicine business, this update is your new go-to starting June 24, 2026.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Easier global approval for dewormers
If you make or test worm‑killing medicines for animals, FDA released a final guidance (GFI #90/VICH GL7) on June 24, 2026 that gives study design recommendations to help effectiveness data be accepted worldwide (including the European Union, Japan, and the United States). This guidance is meant to make it easier and faster for veterinary drug makers and veterinarians to show products work, which the notice says will save time and money.
No new paperwork under PRA
The guidance states it contains no new collection of information under the Paperwork Reduction Act. It refers to previously approved FDA information collections in 21 CFR part 514 under OMB control number 0910-0032, so affected companies will not face new paperwork from this guidance.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-12677, Agency Information Collection Activity: Native American Direct Loan (NADL) Processing Requirements
The VA is renewing its info collection for the Native American Direct Loan program, which helps Native American Veterans buy or improve homes on tribal lands. This update keeps the process smooth without changes, asking for proof of tribal membership and land ownership. If you’re a Native American Veteran using this loan, get ready to share your info by July 24, 2026, with no extra costs expected.
Next: 2026-12679, International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Bovines; Guidance for Industry; Availability
The FDA just released new guidance to help companies test worm-killing medicines for cows. This makes it easier for drug makers worldwide to prove their products work, speeding up approvals and keeping cattle healthy. Farmers, vets, and drug companies should watch for these changes starting now—no extra costs, just clearer rules!